Cerus

Cerus

Biotechnologisch onderzoek

Concord, California 9.453 volgers

At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe.

Over ons

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Branche
Biotechnologisch onderzoek
Bedrijfsgrootte
201 - 500 medewerkers
Hoofdkantoor
Concord, California
Type
Naamloze vennootschap
Opgericht
1992
Specialismen
blood safety, pathogen inactivation, hospital safety, patient safety, pandemic preparedness, plasma, pathogen reduction, blood supply, healthcare, public health, transfusion medicine, platelets en bleeding

Locaties

Medewerkers van Cerus

Updates

Gerelateerde pagina’s

Vergelijkbare pagina’s

Door vacatures bladeren

Aandeel

CERS

NASDAQ

20 minuten vertraging

US$ 1,82

0,09 (5,202%)

Opening
1,71
Laag
1,71
Hoog
1,849

Gegevens van Refinitiv

Bekijk meer informatie over Bing